<DOC>
	<DOCNO>NCT00637988</DOCNO>
	<brief_summary>This study evaluate PGE2 production , COX-2 enzyme activity PCNA expression Barrett 's metaplastic tissue . All patient baseline endoscopy multiple biopsy . The patient receive four dosing regimen ( esomeprazole , esomeprazole aspirin , esomeprazole rofecoxib , rofecoxib alone ) consecutively 10 day dose period , whilst undergo follow endoscopy multiple biopsy .</brief_summary>
	<brief_title>Barrett 's Esophagus - 315 - 3 Way Cross Over</brief_title>
	<detailed_description />
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rofecoxib</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>A biopsyproven diagnosis Barrett 's esophagus segment length great 2cm dysplasia adenocarcinoma . Clinically normal laboratory result physical finding screen . A history esophageal , gastric duodenal surgery , include antireflux surgery endoscopic antireflux procedure , except simple closure ulcer . Evidence follow disease condition : Barrett 's esophagus le great 2cm positive high grade dysplasia adenocarcinoma Signs symptom gastric outlet obstruction Active peptic ulcer disease severe liver disease Pancreatitis Malabsorption Active inflammatory bowel disease Severe pulmonary , cardiovascular renal disease Impaired renal function abnormal urine sediment repeat examination esophageal stricture active , severe esophagitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Barrett 's Esophagus</keyword>
	<keyword>Nexium</keyword>
</DOC>